- Home
- TNGX vs EFSCP Comparison
TNGX vs EFSCP Comparison
Compare TNGX & EFSCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- EFSCP
- Stock Information
- Founded
- TNGX 2014
- EFSCP N/A
- Country
- TNGX United States
- EFSCP United States
- Employees
- TNGX N/A
- EFSCP 1256
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- EFSCP Major Banks
- Sector
- TNGX Health Care
- EFSCP Finance
- Exchange
- TNGX Nasdaq
- EFSCP Nasdaq
- Market Cap
- TNGX 351.2M
- EFSCP N/A
- IPO Year
- TNGX N/A
- EFSCP N/A
- Fundamental
- Price
- TNGX $6.01
- EFSCP $20.60
- Analyst Decision
- TNGX Strong Buy
- EFSCP
- Analyst Count
- TNGX 6
- EFSCP 0
- Target Price
- TNGX $12.20
- EFSCP N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- EFSCP N/A
- Earning Date
- TNGX 08-06-2025
- EFSCP N/A
- Dividend Yield
- TNGX N/A
- EFSCP N/A
- EPS Growth
- TNGX N/A
- EFSCP N/A
- EPS
- TNGX N/A
- EFSCP N/A
- Revenue
- TNGX $40,990,000.00
- EFSCP N/A
- Revenue This Year
- TNGX N/A
- EFSCP N/A
- Revenue Next Year
- TNGX N/A
- EFSCP N/A
- P/E Ratio
- TNGX N/A
- EFSCP N/A
- Revenue Growth
- TNGX 10.09
- EFSCP N/A
- 52 Week Low
- TNGX $1.03
- EFSCP N/A
- 52 Week High
- TNGX $12.02
- EFSCP N/A
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- EFSCP 68.54
- Support Level
- TNGX $5.34
- EFSCP $20.30
- Resistance Level
- TNGX $6.40
- EFSCP $20.49
- Average True Range (ATR)
- TNGX 0.50
- EFSCP 0.11
- MACD
- TNGX -0.02
- EFSCP 0.06
- Stochastic Oscillator
- TNGX 84.08
- EFSCP 100.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About EFSCP Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.